452-11-9

Usage

Uses

Used in Pharmaceutical Industry:
3-Fluoro-4-methoxyphenol is used as a key intermediate in the synthesis of non-peptidic NPBWR1 (GPR7) antagonists. These antagonists are important for the development of drugs targeting the NPBWR1 receptor, which is implicated in various physiological processes and diseases. By modulating the activity of this receptor, non-peptidic NPBWR1 antagonists have the potential to treat a range of conditions, making 3-fluoro-4-methoxyphenol a valuable component in the creation of novel therapeutic agents.

InChI:InChI=1/C7H7FO2/c1-10-7-3-2-5(9)4-6(7)8/h2-4,9H,1H3

Upstream product

• 366-99-4 3-fluoro-4-methoxyaniline 
• 455-93-6 2-fluoro-1-methoxy-4-nitrobenzene 
• 2357-52-0 3-fluoro-4-methoxyphenyl bromide 
• 367-12-4 2-fluorophenol 
• 351-54-2 3-fluoro-p-anisaldehyde 
• 34036-07-2 3,4 difluorobenzaldehyde 
• 946833-20-1 acetic acid 3-fluoro-4-methoxyphenyl ester 
• 321-28-8 1-fluoro-2-methoxybenzene 

Downstream Products

• 327-85-5 4-(2,6-diiodo-4-nitro-phenoxy)-2-fluoro-1-methoxy-benzene 
• 170795-17-2 2-[(3-Fluoro₄-methoxy)phenoxy]tetrahydropyran 
• 866768-91-4 2,4,6-Tris-(3-fluoro-4-methoxy-phenoxy)-[1,3,5]triazine 
• 1369628-59-0 1-(4-fluoro-2-hydroxy-5-methoxyphenyl)ethanone 
• 946833-20-1 acetic acid 3-fluoro-4-methoxyphenyl ester 
• 917925-60-1 4-(2-fluoro-3-methoxy-6-methoxymethoxy-benzoyl)-benzoic acid methyl ester 
• 1185836-60-5 2-bromo-5-fluoro-4-methoxyphenol 
• 133788-99-5 2-fluoro-1-methoxy-4-methoxymethoxy-benzene 
• 348-95-8 4-(3-fluoro-4-methoxy-phenoxy)-3,5-diiodo-aniline; hydrochloride 
• 127557-02-2 4-(3-Fluoro-4-methoxy-phenoxy)-butyric acid 

Relevant academic research and scientific papers

AMINATION AND HYDROXYLATION OF ARYLMETAL COMPOUNDS

In one aspect, the present disclosure provides methods of preparing a primary or secondary amine and hydroxylated aromatic compounds. In some embodiments, the aromatic compound may be unsubstituted, substituted, or contain one or more heteroatoms within the rings of the aromatic compound. The methods described herein may be carried out without the need for transition metal catalysts or harsh reaction conditions.

Rapid heteroatom transfer to arylmetals utilizing multifunctional reagent scaffolds

Arylmetals are highly valuable carbon nucleophiles that are readily and inexpensively prepared from aryl halides or arenes and widely used on both laboratory and industrial scales to react directly with a wide range of electrophiles. Although C-C bond formation has been a staple of organic synthesis, the direct transfer of primary amino (-NH2) and hydroxyl (-OH) groups to arylmetals in a scalable and environmentally friendly fashion remains a formidable synthetic challenge because of the absence of suitable heteroatom-transfer reagents. Here, we demonstrate the use of bench-stable N-H and N-alkyl oxaziridines derived from readily available terpenoid scaffolds as efficient multifunctional reagents for the direct primary amination and hydroxylation of structurally diverse aryl- and heteroarylmetals. This practical and scalable method provides one-step synthetic access to primary anilines and phenols at low temperature and avoids the use of transition-metal catalysts, ligands and additives, nitrogen-protecting groups, excess reagents and harsh workup conditions.

NOVEL NUCLEOSIDE PHOSPHORAMIDATE COMPOUND AND USE THEREOF

The present invention provides a novel nucleoside phosphoramidate compound, or a stereoisomer, salt, hydrate, solvate or crystal thereof for the treatment of Flaviviridae family viral infection, especially hepatitis C viral infection. The present invention also provides the pharmaceutical composition comprising a compound of the present invention, or a stereoisomer, salt, hydrate, solvate or crystal thereof and a use of the compound or the composition of the present invention in the treatment of Flaviviridae family viral infection, especially hepatitis C viral infection. The compound of the present invention has a good anti-HCV effect.

LABELED PKG-1-ALPHA-BINDING COMPOUNDS AND THEIR USE IN IMAGING AND QUANTIFYING PAIN

The present invention relates to the use of compounds that selectively bind to activated protein kinase G1 alpha for imaging the anatomic basis for chronic pain. Such imaging may also be used to objectively quantify chronic pain. Specifically, fluorine-18

Continuous-flow synthesis of functionalized phenols by aerobic oxidation of grignard reagents

Phenols are important compounds in chemical industry. An economical and green approach to phenol preparation by the direct oxidation of aryl Grignard reagents using compressed air in continuous gas-liquid segmented flow systems is described. The process tolerates a broad range of functional groups, including oxidation-sensitive functionalities such as alkenes, amines, and thioethers. By integrating a benzyne-mediated in-line generation of arylmagnesium intermediates with the aerobic oxidation, a facile three-step, one-flow process, capable of preparing 2-functionalized phenols in a modular fashion, is established. Putting on airs: Aerobic oxidation of (hetero)aryl Grignard reagents using compressed air proceeds with a gas-liquid continuous-flow system, thus enabling preparation of fucntionalized phenols. By integrating an in-line generation of ArMgBr intermediates with the aerobic oxidation, ortho-functionalized phenols can be assembled. The method demonstrates good functional-group (FG) compatibility, mild reaction conditions, and short reaction times.

PYRAZINES AS DELTA OPIOID RECEPTOR MODULATORS

Disclosed are compounds, compositions and methods for treating various diseases, syndromes, conditions and disorders, including pain. Such compounds are represented by Formula I as follows: wherein R1, R2, R3, L, X, and Y are defined herein.

Neuronal Pain Pathway Modulators

The present invention relates to compounds that may be used to inhibit activation of protein kinase G (“PKG”). It is based, at least in part, on the discovery of the tertiary structure of PKG and the identification of molecules that either bind to the act

The element effect and nucleophilicity in nucleophilic aromatic photosubstitution (SNAR*). Local atom effects as mechanistic probes of very fast reactions

(Chemical Equation Presented) Photoreactions of 4-nitroanisole and the 2-halo-4-nitroanisoles (halogen = F, Cl, Br, and I) with the nucleophiles hydroxide ion and pyridine have been investigated quantitatively to extend the findings recently communicated for cyanide ion. The halonitroanisoles on excitation form triplet π,π* states, which undergo substitution of the halogen by nucleophiles. Chemical yields of photoproducts, Stern-Volmer kinetic plots, triplet lifetimes, and triplet yields are reported for the five compounds with the three nucleophiles. Following a standard kinetic treatment, 73 rate constants are determined for elementary reactions of the triplets including quenching and various nucleophilic addition processes. The photoadditions are roughly 14 orders of magnitude faster than thermal counterparts. Rate constants for attack at the fluorine-bearing carbon of triplet 2-fluoro-4-nitroanisole are 2.9 × 109, 1.3 × 109, and 6.3 × 108 M-1 s-1 for cyanide ion, hydroxide ion, and pyridine, respectively. The relative rates for attack at the halogen-bearing carbons for F/Cl/Br/I are 27:1.9:1.9:1 (cyanide ion), 29:2.6:2.4:1 (hydroxide ion), and 39:3.9: 3.5:1 (pyridine), respectively. The relative nucleophilicities vary somewhat with the attack site; they are about 5:2:1 for cyanide ion, hydroxide ion, and pyridine for attack at the halogen-bearing carbons. The trend of the element effect opposes that of aliphatic substitution and elimination but is similar in size and parallel to that of thermal nucleophilic aromatic substitution. Relative nucleophilicities in the photoreactions are also similar to those of comparable but vastly slower thermal reactions. The findings imply that the efficiency-determining step of the halogen photosubstitution is simple formation of a σ-complex through electron-paired bonding within the triplet manifold.

PHARMACEUTICAL COMPOUNDS

The invention provides a compound of the formula (I) or a salt, solvate, tautomer or N-oxide thereof; wherein A is a saturated hydrocarbon linker group; E is a monocyclic or bicyclic carbocyclic or heterocyclic group; L1 is a bond or a linker selected from C1-C4 alkenylene, C1-C4 alkynylene, -CONR’, -NR’CO, -S, -C(O)-, -C(NR11)-, -C(S)-, -N(R11)2, C(=CHR11), -SO- and -SO2-; or L1 together with t R16 forms and 8-12 membered fused bicyclic heteroaryl ring system; L3 is a bond or a linker selected from CONH and HNCO; provided that L1 and L3 cannot both be linkers simultaneously; and provided also that L1 and L3 cannot both be a bond simultaneously; R16 is an optionally substituted 5- to 12-membered monocyclic or bicyclic carbocyclic or heterocyclic ring; L2 is absent or is a linker selected from C]-C4 alkylene, Ci-C4 alkenylene, Ci-C4 alkynylene, -CONR’-, -NR’CO-, -O-, -S-, -C(O)-, C(=CHR11), C(S)-, -N(R11)2, C3-4 cycloalkanediyl, -SO- and -SO2-; R17 is absent or is C1-6 alkyl or an optionally substituted 5 to 12 membered carbocyclic or heterocyclic ring; provided that when R17 is absent, then L2 is also absent; and R2, R3, R4, R5, R11 and R’ are as defined in the claims.

Regiospecific hydroxylation in aromatic series by the organosilicon pathway

Regiospecific hydroxylation of functional arylsilanes by hydrogen peroxide (30percent) or by bis(trimethylsilyl) peroxide, in the presence of a stoichiometric amount of fluoride ions, gives the corresponding phenols in good yields. regiospecific hydroxylation / phenol / hydrogen peroxide / bis(trimethylsilyl) peroxide / arylsilane